Together these results suggest that patients with aNSCLC whose tumors harbor KRAS mutations may have particularly favorable outcomes with CIT [26], which is distinct from EGFR-mutated NSCLC [26, 27]. Here, EGFR is linked to non-small cell lung carcinoma.